AlphaFold predicted structure
APOC3 · P02656

Mean pLDDT
67.6/ 100
Low
99 residues
Confidence breakdown
- Very high(≥ 90)0%
- Confident(70–90)33%
- Low(50–70)64%
- Very low(< 50)3%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
apolipoprotein C3
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Hereditary systemic amyloidosis
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedPeriodic fever syndromes
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedFamilial hypercholesterolaemia
apolipoprotein c-III deficiency
hypertriglyceridemia
coronary artery disorder
familial chylomicronemia syndrome
Hypercholesterolemia
cardiovascular disorder
cholesterol-ester transfer protein deficiency
metabolic disease
diabetes mellitus
hyperalphalipoproteinemia
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Apolipoprotein C-III
Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013)
APOC3 · P02656

Mean pLDDT
67.6/ 100
Low
99 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0